Table 6 Analysis of risk factors for recurrence in bots patients underwent FSS
| Â | Recurrence (%) | P | ||||||
|---|---|---|---|---|---|---|---|---|
FIGO stage | I | II | III | Â | 0.729 | |||
| Â | 9.6(5/52) | 0(0/1) | 0(0/5) | Â | Â | |||
Histology | Mucinous | Serous | Seromucinous | Â | 0.749 | |||
| Â | 5.6(1/18) | 10.5(4/38) | 0(0/2) | Â | Â | |||
Lesion site | Unilateral | Bilateral | Â | Â | 0.175 | |||
| Â | 5.1(2/39) | 15.8(3/19) | Â | Â | Â | |||
Extent of ovarian surgery in FSS | Unilateral oophorocystectomy | Bilateral oophorocystectomy | Unilateral oophorectomy | Unilateral oophorectomy + contralateral oophorocystectomy | 0.901 | |||
| Â | 7.7(1/13) | 12.5(1/8) | 5.3(1/19) | 11.1(2/18) | Â | |||
Interval from surgery to IVF (years) | ≤ 1 | >1,≤2 | >2 |  | 0.982 | |||
| Â | 8.0(2/25) | 10.0(1/10) | 8.7(2/23) | Â | Â | |||
Number of stimulation cycles | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 0.239 |
| Â | 10.3(3/29) | 0(0/11) | 0(0/6) | 0(0/5) | 25.0(1/4) | 0(0/1) | 50(1/2) | Â |
Peak E2 level in ovarian stimulation(pg/ml) | ≤ 500 | >500, ≤1000 | >1000, ≤1500 | >1500, ≤2000 | >2000, ≤2500 | >2500 |  | 0.578 |
| Â | 13.6(3/22) | 7.1(1/14) | 0(0/6) | 0(0/3) | 25.0(1/4) | 0(0/9) | Â | Â |